Search Results 281-290 of 8485 for Apixaban

  1. Pexidartinib (oral route) - Side effects & dosage - Mayo Clinic

    Description. Pexidartinib is used to treat tenosynovial giant cell tumor (TGCT) that is not likely to improve with surgery. TGCT is also known as giant cell ...

  2. CLN-049 In Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS) - Mayo Clinic

    Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...

  3. Publications - Neena S. Abraham, M.D. - Mayo Clinic

    Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Nonvalvular Atrial Fibrillation. Chest. 2016 Dec; 150 (6):1302 ...

  4. A Study Of Acalabrutinib And Vistusertib In Subjects With Relapsed/Refractory B-cell Malignancies - Mayo Clinic

    Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...

  5. Heart Disease Clinical Trials - Mayo Clinic Research

    The investigators are conducting this study to determine if the anticoagulant medication Apixaban is more effective at reducing MRI detected brain lesions ...

  6. Tenecteplase (intravenous route) - Side effects & uses - Mayo Clinic

    Apixaban; Ardeparin; Argatroban; Bemiparin; Betrixaban; Bivalirudin; Caplacizumab-yhdp; Certoparin; Cilostazol; Clopidogrel; Curcumin; Dabigatran Etexilate ...

  7. Salicylic acid and sulfur (topical route) - Side effects & dosage - Mayo Clinic

    Apixaban; Ardeparin; Aspirin; Balsalazide; Bemetizide; Bemiparin; Bendroflumethiazide; Benzthiazide; Betrixaban; Bismuth Subsalicylate; Bromfenac; Budesonide ...

  8. A Study Of Taxane, Trastuzumab, And Pertuzumab With Or Without Atezolizumab In Treating Metastatic Breast Cancer Patients - Mayo Clinic

    Immunotherapy with trastuzumab, pertuzumab, and atezolizumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to ...

  9. To Evaluate The Efficacy And Safety Of Parsaclisib And Ruxolitinib In Participants With Myelofibrosis - Mayo Clinic

    The purpose of this study is to compare the effectiveness of parsaclisib when combined with ruxolitinb versus placebo combined with ruxolitinib in participants ...

  10. Randomized Study To Assess The Safety, Pharmacokinetics/Dynamics Of DS-1040b In Subjects With Acute Submassive Pulmonary Embolism - Mayo Clinic

    Subjects who within 48 hours of randomization have used an anti-Factor IIa agent such as dabigatran or an anti-FXa agent such as rivaroxaban, apixaban, or ...